Welcome to the international HTA database

Showing [21797 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Ambrisentan (Volibris) in the treatment of pulmonary arterial hypertension]
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Ambulatory blood pressure monitoring (ABPM) in the identification of circadian patterns in patients with arterial hypertension: evaluation of safety, effectiveness, and efficiency]
2009	Committee for New Health Technology Assessment (CNHTA)	[Ambulatory esophageal multichannel impedence pH monitoring]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ambulatory oxygen therapy in COVID-19]
1998	Basque Office for Health Technology Assessment (OSTEBA)	[Ambulatory ultrasound in Basque country: current status, recommendations on its use and practice]
2009	Committee for New Health Technology Assessment (CNHTA)	[AMH]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Amifampridine (Firdapse) for the treatment of Lambert Eaton Myasthenic Syndrome]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Amikacin sulfate (Mycobacterium avium Complex [MAC] lung infections) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Amivantamab (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Amotosalen (Intercept) for the inactivation of pathogens for transfusion therapy]
2007	Andalusian Health Technology Assessment Area (AETSA)	[AmpliChip CYP450: Cytochrome P450 genotyping in psychiatric patients]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Amyloid PET in dementia of unclear aetiology (Addendum to Commission E18-03)]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Amyloid PET in dementia of unclear aetiology]
2014	Basque Office for Health Technology Assessment (OSTEBA)	[An evaluation of intensity-modulated radiotherapy (IMRT)]
2015	Basque Office for Health Technology Assessment (OSTEBA)	[An evaluation of the efficacy of psychosocial techniques (cognitive rehabilitation vs. psychoeducation) as an additional treatment to pharmacological treatment in bipolar disorder]
1998	Andalusian Health Technology Assessment Area (AETSA)	[An evidence-based guideline on unstable angina management]
2016	Basque Office for Health Technology Assessment (OSTEBA)	[An image-guided system for liver surgery (CAScination)]
2016	The Swedish Council on Health Technology Assessment (SBU)	[Anal sphincter injuries]
2011	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis and development of preventive activities in primary care. Review of the preferential offer and its support software (PAP)]
2001	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis and review of protocols and quality standards in the diagnostic process for the detection of cervical cancer]
2014	National Evidence-based Healthcare Collaborating Agency (NECA)	[Analysis for healthcare safety management system]
2008	Andalusian Health Technology Assessment Area (AETSA)	[Analysis of APC mutations to perform prophylactic colectomy in subjects at risk for colorectal cancer]
2017	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Analysis of clinical studies of medical devices]
2018	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Analysis of diagnostic performance of transbronchial lung biopsy using cryoprobe (cryobiopsy) in the study of diffuse lung diseases]
2006	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Analysis of factors that can influence the levels of TSH in the neonatal period]
2011	The Swedish Council on Health Technology Assessment (SBU)	[Analysis of fetal DNA in maternal blood: non-invasive fetal diagnostic tests for blood group and sex determination]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Analysis of health and socioeconomic factors influencing the progressive increase in frequentation of hospital emergency services]
2008	Andalusian Health Technology Assessment Area (AETSA)	[Analysis of RET mutations to perform prophylactic thyroidectomy in individuals at risk for medullary thyroid cancer]
2001	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of surgical antibiotic prophylaxis]
2008	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of telemedicine applications in the management-coordination of specialized and primary care. Appraisal of results and costs of pre-existing experiences (teleophthalmology)]
2009	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the adequacy of diagnostic indications of the following application techniques of cerebral MR: MR spectroscopy, diffusion, gadolinum perfusion and cerebral functional-activation MR in advanced neurological diagnosis]
2001	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the appropriateness of hospital admissions from emergencies]
1996	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the cost-effectiveness of the non-mydriatic retinal camera for diabetic retinopathy]
2023	Center for Drug Evaluation (CDE)	[Analysis of the effectiveness of various hemophilia treatments in Taiwan]
2018	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Analysis of the efficacy and safety of orthodontic-orthopedic maxillary expansion devices as an alternative to adenotonsillectomy and/or pharmacological treatment in the management of sleep apnea-hypopnea syndrome in pediatric patients]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Analysis of the efficacy and safety of robotic spinal surgery]
1998	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the efficacy of the treatments and costs of Alzheimer's disease in the Basque Country]
2017	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the efficacy, safety and efficiency of stabilisation of intervertebral discs using Discogel]
1999	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the efficiency of the laboratory test in emergency care]
2005	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the evolution of main causes of mortality in 65 and older people in the Basque Country (1986-2001)]
2000	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the scientific evidence on the effectiveness and efficiency of different kinds of hip prosthesis. Recommendations]
2013	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the status, systematic review and validation of a diagnostic algorithm for pulmonary thromboembolism (PTE) in the hospital emergency services of the Basque Health Service]
2000	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the use of clinical protocols for monitoring the chronically ill in primary health care]
2001	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of the use of simple cranium, chest and abdomen radiology in emergency hospital services]
2001	Basque Office for Health Technology Assessment (OSTEBA)	[Analysis of tuberculosis isolation and prophylaxis techniques at a hospital level]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Andexanet alfa (acute major bleeding) - Addendum to Commission A19-76]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V]
2022	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Anesthesia information management systems]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angiogenesis inhibitors (bevacizumab - ranibizumab) in neovascular glaucoma and corneal neovascularization]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Angiographic profile of patients undergoing drug eluting stent implantation in Spain. Variability of off-label indications]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty and stenting in patients with carotid artery stenosis]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty with stent placement in patients with carotid artery disease]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty with stent placement in patients with deep vein thrombosis]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Angiotensin II acetate (hypotension) - Benefit assessment according to §35a Social Code Book V]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Anifrolumab (systemic lupus erythematosus) - Addendum to Commission A22-35]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Anifrolumab (systemic lupus erythematosus) - Benefit assessment according to §35a Social Code Book V]
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Annual Report 2010. German version.]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Anorectal biofeedback therapy in primary constipation]
2012	Institut national d'excellence en sante et en services sociaux (INESSS)	[Anti-angiogenic drugs in the treatment for age-related macular degeneration: issues associated with their use in Québec]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Anti-d immunoglobulin in pregnancy and immune thrombocytopenia]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Anti-GD2 immunotherapy in patients with high risk neuroblastoma]
2009	Committee for New Health Technology Assessment (CNHTA)	[Anti-Heparin/Platelet Factor 4 antibody assey]
2003	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Anti-immunoglobulin E (omalizumab) for the treatment of allergic asthma in adults]
2009	Committee for New Health Technology Assessment (CNHTA)	[Anti-saccharomyces cerevisiae antibody test]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Antiangiogenic drugs in refractory age-related macular degeneration]
2010	Norwegian Knowledge Centre for the Health Services (NOKC)	[Antibiotic therapy in hospital, oral versus intravenous treatment]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Antibodies to pgp9.5 in small fiber neuropathy]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Antibody-coated drug-eluting stents for treatment of coronary artery stenosis]
2012	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Antibody-eluting stents for treatment of coronary artery stenosis in patients with high risk of restenosis - rapid report]
2012	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Antibody-eluting stents for treatment of coronary artery stenosis in patients with high risk of restenosis - rapid report]
2015	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	[Antigermix – disinfection of endocavitary ultrasonography probes]
2020	National Committee for Technology Incorporation (CONITEC)	[Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]
2011	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Antipsychotic polypharmacy in the treatment of schizophrenia]
2021	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Antithrombotic treatments following heart valve replacement surgeries]
2009	Committee for New Health Technology Assessment (CNHTA)	[Antroduodenal manometry]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Aortic valve replacement with rapid deployment or sutureless valves]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Addendum to Commission A19-09]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Addendum to Commission A20-20]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2010	Committee for New Health Technology Assessment (CNHTA)	[APC gene,mutation[sequencing]]
2012	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2010	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Applicability of sentinel-lymph-node detection and biopsy in the treatment of vulval cancer]
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	[Application of genetic algorithms and expert systems in medical care. Clinical applications of artificial intelligence]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Application of genetic algorithms and expert systems in medical care. Clinical applications of artificial intelligence]
2000	Basque Office for Health Technology Assessment (OSTEBA)	[Appraisal of the variability and suitability of prescribing antimicrobials in primary health care in the Basque Country]
2008	Basque Office for Health Technology Assessment (OSTEBA)	[Approach to personality disorders in the mental health system of the Basque Country]
2023	Andalusian Health Technology Assessment Area (AETSA)	[Appropiate indication for leadless pacemaker. Systematic review and appropriateness criteria]
2010	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Appropriate use of diagnostic imaging technologies in acute abdominal pain]
2010	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Appropriate use of diagnostic imaging technologies in primary and secondary care : ultrasonography in breast pathology]
2005	Andalusian Health Technology Assessment Area (AETSA)	[Appropriate use of Factor VIII for treatment of hemophilia - A consensus conference]
2000	Andalusian Health Technology Assessment Area (AETSA)	[Appropriate use of Factor VIII in the treatment of haemophilia. A Literature review and opinions of an expert panel on the correct use of different preparations of Factor VIII]
2009	Andalusian Health Technology Assessment Area (AETSA)	[Appropriate use of recombinant activated factor VII in nonhaemophilic patients]
2009	Andalusian Health Technology Assessment Area (AETSA)	[Appropriateness criteria for vertebral arthrodesis]
2009	Canary Health Service	[Appropriateness of the indication of physical therapy techniques]
2009	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Appropriateness use standards for health technologies : appropriate admission explicit criteria for heart failure (HF)]